Atlas Trials

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

1 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)

RecordFirmDate
Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden (NCT03263091)Kyntra Bio2018-01-29

Track Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts) automatically

Every clearance here is in the API, with alerts when new ones post.